Cetuximab is a chimeric monoclonal antibody that selectively binds to EGFR, which can effectively block the activation of EGFR and its downstream signaling pathways, thereby inhibiting EGFR-related development and cancer progression.196 Cetuximab is currently the most commonly used anti-EGFR antibody for surface modification of nanocarriers. This evidence concerns the gene EGFR and cancer.